XRP Healthcare Magazine’s Post

It's always a pleasure to be back at TINS: Technology Innovation Studio, Unison's second home, with Suman Lal, Salma B., and the TINS team in #KendalSquare, #Cambridge, "the most innovative square mile on the planet". The Festival of #Genomics and #Biodata last week was excellent. Great to reconnect with Simeón Baker from Genomics England, Matt Newman and the team from DNAnexus, and to make many new contacts at the Broad Institute of MIT and Harvard, Massachusetts Institute of Technology, Harvard Medical School, Memorial Sloan Kettering Cancer Center, Takeda and Johnson & Johnson, not to mention the time with Shwen Gwee, as always! Next Thursday, June 27th, I'm hosting a networking, talk and collaborative brainstorming session on the Value Potential of Integrative #Multiomic Analysis in #BioPharma R&D at TINS: Technology Innovation Studio, CIC (Cambridge Innovation Center). We'll cover: 🧬 The theory behind #multiomic analysis and its value potential in drug development. 🌐 The current landscape, including challenges such as data fragmentation and accessibility. 🤖 The potential role of #FoundationModels and #AI / #machinelearning. 🔮 Envisioning of a future integrative analysis state. 🚀 The necessary technological advancements to achieve the future state. 🔗 How we can bridge critical gaps to achieve this vision. If any of the above are of interest to you, and you're in #Boston or #Cambridge, it would be great to see you there.

[PORTFOLIO] 🚀 We are excited to share that our portfolio company Bioptimus has successfully raised a total of $76M, a significant funding milestone reached through its latest $41M cash injection. This investment will propel Bioptimus forward in its mission to develop universal AI foundation models for biology. The company successfully released a best-in-class foundation model for histology, H-Optimus-0, less than a year since the company's inception and is now poised to release a breakthrough new multi-scale, multi-modal foundation model for biology in 2025. More information 👉 https://lnkd.in/eUBRBwNt Bpifrance is proud to have been supporting Bioptimus since day one and to continue doing so. Cathay Innovation, Sofinnova Partners, Andera Partners, Hitachi Ventures, Boom Capital, Pomifer Capital Nicolas Dufourcq, Paul-François Fournier, Maïlys Ferrere, Laurent Higueret, Marine Choplain, Adrien de Saint Victor #GenAI #foundationmodels #techbio

What if you had a Nextflow expert as your bioinformatics intern? With Seqera’s recent acquisition of Tinybio, we’re working to bring GenAI to your Nextflow workflows, enabling you to start developing complex pipelines with just a few simple prompts. How will you deploy your intern? #Bioinformatics #Nextflow #GenAI #Seqera

Here are some of the most significant funding rounds from the past week, with artificial intelligence and biotech dominating the scene. Check out who’s making waves in the world of innovation: 1️⃣ OpenAI – $6.6B (AI): Massive raise at a $157B valuation, led by Thrive Capital. OpenAI continues to push boundaries in generative AI, despite internal restructuring. 2️⃣ poolside – $500M (AI): Poolside closed a $500M Series B led by Bain Capital Ventures, specializing in AI software for programmers. 3️⃣ Kailera Therapeutics – $400M (Biotech): Boston-based biotech focused on therapies for chronic weight management with a massive Series A launch. 4️⃣ Aktis Oncology – $175M (Biotech): Boston’s Aktis Oncology continues its work on radiopharmaceuticals to treat solid tumors. 5️⃣ Impulse Space – $150M (Space): Developing orbital transfer vehicles, Impulse Space is raising the bar in space tech. #PulseRecruitment #Recruitment #Tech #TechRecruitment #ITRecruitment

things getting more and more interesting in our field #bioinformatics #nextflow #genomics

𝗔𝗤𝗘𝗠𝗜𝗔 𝗵𝗶𝘁𝘀 $𝟭𝟬𝟬 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝗳𝘂𝗻𝗱𝗶𝗻𝗴 𝗺𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲: AQEMIA, a pioneering techbio that teaches atomic scale physics to a generative AI to invent innovative medicines, announces two major milestones: $100 million in cumulative funding and the beginning of a global expansion starting with London (United Kingdom). 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://lnkd.in/dg22YqHh AQEMIA, Maximilien Levesque, Emmanuelle Martiano Rolland, Jacky Abitbol, Cathay Innovation, Wendel, Bpifrance Large Venture, Eurazeo, Elaia

🎉 Newlab Member News Alert! 🎉 Congratulations to Caladan Bio on the launch of The Caladan 250 and on securing a $5M seed round led by Twelve Below with participation from Lerer Hippeau, Collaborative Fund, Wireframe Ventures, Ritual Capital and Factorial! About the Caladan 250: The Caladan 250 is a high throughput benchtop bioreactor system designed to increase experimentation throughput and enhance data capture - all while leveraging AI and ML. "As the tools to edit cells become commonplace, the focus needs to shift to optimizing biomanufacturing. At Caladan, we believe that for synthetic biology companies, the process is the product," says Michael Kobida, Co-Founder and CEO of Caladan Bio. Join us in celebrating this milestone achievement with Caladan Bio! Learn how you can join Newlab’s community of founders changing the world: https://lnkd.in/gbNRFZs6 Read more about Caladan's last round here: https://lnkd.in/gh8PxTgB

🎉 Excited to share that we've just hit a remarkable $76M funding milestone, with a fresh $41M round led by Cathay Innovation, with participation from prominent investors, including Sofinnova Partners, Bpifrance, Andera Partners, Hitachi Ventures, Boom Capital, Pomifer Capital, Sunrise, and angel entrepreneurs Emmanuel Cassimatis and Thomas Wolf. This comes less than a year after our seed round, demonstrating the tremendous confidence in our vision. Since launching the largest AI foundation model for pathology in July, we've been working tirelessly behind the scenes. Now, we're on the cusp of something truly groundbreaking: a new multi-scale, multi-modal foundation model for biology, set to launch this year. We're not just building technology, we're creating a new paradigm for biological innovation. We’re grateful to our incredible team, investors, and partners who believe in our mission to build the world's first universal AI foundation model for biology. This is just the beginning! 🧬🚀 📰 Read the press release: https://lnkd.in/ecH37kuW #AI #Biotech #Innovation #FundingNews #FoundationModels

I had the pleasure to attend the BioIndustry Association (BIA) #Techbio conference and AlbionVC's recent techbio breakfast, both of which highlighted the exciting potential of computational drug discovery. Key takeaways: 🧠 Actionable insights are key: With knowledge becoming commoditised, execution is paramount in this nascent industry 🧬 Techbio's broad impact: Developments in early-stage drug discovery are incredibly exciting (a highlight being Isomorphic Labs' keynote on their latest multi-omic work with AlphaFold 3), though techbio is revolutionising the entire life sciences supply chain, from early R&D to real-time monitoring 🧪 Platform vs. product: Defining a company's focus remains crucial - but may well shift - especially as datasets expand, and confidence grows in the outputs and findings of computational modelling 🤝 Strategic partnerships: Securing aligned advice, support, and investment is crucial. Clear expectations from the outset are vital to bridge the knowledge gap between tech and bio stakeholders and navigate the unique challenges of this field We are still very much at the foothills of the techbio journey, and I'm looking forward to what the next twelve months bring! #Techbio2024 #DrugDiscovery #PrecisionMedicine #EngineeringBiology #AI #Data #Genomics

Pierre Socha, Amadeus Partner, puts the biotech public markets under the microscope in this European Life Sciences Review article🔬 Despite biotech IPO challenges, venture capital is fuelling innovation in AI and synthetic biology, with the latter poised to become a $30 billion industry by 2026. This surge is transforming healthcare delivery, making it more accessible outside conventional hospitals. We're proud to support these groundbreaking innovations, delivered by the pioneering founders we back 🤝 Read the article here⬇️ https://bit.ly/3z4HmRR #LifeSciences #HealthTech #VentureCapital